LianBioOTC Pink - Limited Information:LIANY
- LAST PRICE0.2976
- TODAY'S CHANGE (%)-0.0024 (-0.8167%)
- Bid / Lots0.2951/ 25
- Ask / Lots0.3595/ 25
- Open / Previous Close0.2997 / 0.3000
- Day Range
- 52 Week Range
- Volume86,828
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LIANY |
|---|---|---|
| 09:32 ET | 26916 | 0.282 |
| 10:33 ET | 5000 | 0.295 |
| 11:32 ET | 100 | 0.2951 |
| 12:24 ET | 6937 | 0.2997 |
| 01:33 ET | 33837 | 0.3 |
| 01:40 ET | 5000 | 0.29706 |
| 02:00 ET | 937 | 0.3 |
| 02:02 ET | 2000 | 0.3 |
| 02:05 ET | 1063 | 0.3 |
| 02:45 ET | 5000 | 0.29755 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
LianBio | 32.4M | -0.4x | --- |
Estrella Immunopharma Inc | 32.2M | -3.8x | --- |
Grace Therapeutics, Inc | 32.8M | -3.0x | --- |
Citius Pharmaceuticals Inc | 31.9M | -0.5x | --- |
Lantern Pharma Inc | 31.8M | -1.7x | --- |
Passage Bio Inc | 33.1M | -0.4x | --- |
Company Information
LianBio is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.
Contact Information
- Headquarters
- 103 Carnegie Center Drive Suite 309, Suite 215PRINCETON, NJ, United States 08540
- Phone
- 609-486-2308
- Fax
- ---
Executives
- Executive Chairman of the Board
- Konstantin Poukalov
- Interim Chief Executive Officer, Director
- Adam Stone
- Interim Chief Financial Officer
- Ehong Gu
- China General Manager
- Jiang Qian
- Chief Business Officer
- Brianne Jahn
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $32.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 108.1M |
LianBio does not pay a dividend. | |
Beta | --- |
EPS | $-0.82 |
Book Value | $2.43 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
